Investing in the development of new antibiotics and their conservation
Setting up a global antibiotic research and development facility
The WHO Global Action Plan on Antimicrobial Resistance (GAP-AMR) that was adopted by the Sixty-Eighth World Health Assembly in May 2015 calls for the creation of new partnerships to foster the development and conservation of antibiotics. To implement this part of the GAP-AMR, WHO and the Drugs for Neglected Diseases Initiative are working on the creation of a ‘Global Antibiotic Research and Development Facility’. This new partnership will develop new antibiotic treatments addressing antimicrobial resistance and promote their responsible use for optimal conservation, while ensuring equitable access for all. The Partnership will stimulate innovation for global needs in the area of antibiotics by ensuring that any new products are also suitable for resource-limited settings.
The Partnership will work closely with all stakeholders – including pharmaceutical and biotechnology companies, other product development partnerships, academia, civil society, and health authorities – from countries of all income levels to develop new antibiotic treatments and to preserve them.
WHO and DNDi are holding a technical consultation on 13 November 2015 in Geneva to mobilize support for the creation of this new partnership: